ubivac Press Releases

Published on March 19, 2025 - 08:32 GMT

UbiVac to present on Dark Genome-derived Dark Matter/Proteome Cancer Immunotherapy at Spring 2025 Venture Forum

UbiVac's DPV-001 is the World's 1st Dark Matter Cancer Immunotherapy in the Clinic - Promising Early Data Supports Phase II Trial PORTLAND, OR, UNITED STATES, March 19, 2025 /⁨EINPresswire.com⁩/ -- UbiVac, www.ubivac.com, a private, clinical-stage Immuno-oncology & Cancer Target Discovery Company, today announced participation in the investor conference. UbiVac’s Commitment to Cancer Treatment UbiVac’s mission is the development of immunotherapies that induce broad immunity against many …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on November 8, 2024 - 00:00 GMT

Promising Phase Ib Data for UbiVac’s DPV-001 in Combination Immunotherapy for Head and Neck Squamous Cell Cancer

UbiVac's DPV-001 Dark Matter combo Immunotherapy triples response rate and progression-free survival over PD-1 alone for patients with r/m head and neck cancer HOUSTON, TX, UNITED STATES, November 7, 2024 /⁨EINPresswire.com⁩/ -- UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company today announced the presentation of updated results from a Phase 1b study evaluating clinical efficacy and safety of DPV-001, UbiVac’s lead investigational cancer vaccine immunotherapy, containing cancer’ …

Distribution channels: Banking, Finance & Investment Industry, Companies ...

Published on April 6, 2024 - 17:19 GMT

DPV-001 Vaccine Containing Cancer’s “Dark Matter” Yields 2 to >3-fold Increased Response Rate for Head and Neck Cancer

Positive Data from Phase Ib Study Evaluating UbiVac’s DPV-001 as Combination Immunotherapy for Head and Neck Squamous Cell Cancer Presented at AACR Meeting PORTLAND, OR, USA, April 6, 2024 /⁨EINPresswire.com⁩/ -- • UbiVac Announces a 2 to >3-fold increase in objective clinical response rates over anti-PD-1 alone, for patients receiving DPV-001 vaccine containing cancer’s “Dark Matter” as combination immunotherapy for recurrent or metastatic HNSCC • Responses were observed in patients that had not …

Distribution channels: Banking, Finance & Investment Industry, Education ...

Published on April 8, 2022 - 16:15 GMT

UbiVac Announces Preliminary Immunological Data from 1st-In-Human Trial of DPV-001 Immunotherapy Trio for Advanced HNSCC

Data from Clinical Trial of DPV-001 & Anti-PD-1 +/- anti-GITR for Head & Neck Squamous Cell Cancer (HNSCC) Presented at American Association for Cancer Research NEW ORLEANS, LOUISIANA, USA, April 8, 2022 /⁨EINPresswire.com⁩/ -- UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that activates and educates the immune system to recognize and destroy cancer, announced that Rom S. Leidner, M.D., Co-Director of the Head and Neck Cancer Program at the Providence …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on October 29, 2020 - 12:30 GMT

FDA Grants Approval for UbiVac Manufactured Coronavirus Vaccine to Start Clinical Trial

Providence St. Joseph Health, one of the national’s leading non-profit health systems, and the Providence Cancer Institute to run Phase 1 clinical trial PORTLAND, OREGON, UNITED STATES, October 29, 2020 /⁨EINPresswire.com⁩/ -- UbiVac Inc., a clinical stage immunotherapy company, is pleased to announce that the FDA has granted approval to commence clinical trials of the CorVax vaccine. UbiVac in collaboration with Providence Cancer Institute, a part of Providence St. Joseph Health ("Providence") …

Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...

Published on October 17, 2020 - 22:18 GMT

Dr Bernard Fox joins CCFDIE Immunotherapy Workshop to Talk UbiVac’s Combination Immunotherapy for Advanced Breast Cancer

China Center for Food and Drug International Exchange hosts International Immunotherapy Experts to Discuss State-of-Art and Future Treatments for Cancer BEIJING, CHINA, October 17, 2020 /⁨EINPresswire.com⁩/ -- UbiVac Inc’s co-founder and CEO, Bernard A. Fox, PhD, joined luminaries and regulatory experts to present work from UbiVac and colleagues at the Chiles Research Institute, during the opening session of the China Center for Food and Drug International Exchange (CCFDIE) Cancer Immunotherapy Workshop …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on October 16, 2020 - 06:22 GMT

Immuno-Oncology Pioneer Dr. Jon M. Wigginton Joins UbiVac’s Board of Directors

Dr. Jon Wigginton, internationally recognized developer of immunotherapies, advisor to MPM Capital and CMO at Cullinan Oncology, to join UbiVac's Board PORTLAND, OREGON, UNITED STATES, October 15, 2020 /⁨EINPresswire.com⁩/ -- UbiVac Inc. is pleased to announce that Dr. Jon M. Wigginton, MD will join UbiVac’s Board of Directors. Dr. Wigginton had previously served on UbiVac’s scientific and business advisory boards. A physician and scientist, he is a leader in the development of combination …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on September 24, 2020 - 19:17 GMT

Triplet Immunotherapy for Metastatic Triple Negative Breast Cancer Presented at Chinese Society for Clinical Oncology

UbiVac CEO discusses how biomarker data and preclinical studies led to a first-in-human Immunotherapy being tested in patients with metastatic breast cancer XIAMEN, CHINA, September 24, 2020 /⁨EINPresswire.com⁩/ -- UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder and CEO, Bernard A. Fox, PhD, will speak at the Chinese Society for Clinical Oncology Conference held 19-26 …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

The Newsroom of UbiVac